Skip to main content
. Author manuscript; available in PMC: 2019 Jan 9.
Published in final edited form as: Nat Med. 2018 Jul 9;24(9):1324–1329. doi: 10.1038/s41591-018-0103-x

Figure 4. eGluCl treatment has no effect on normal brain function.

Figure 4

(a) Absolute increase in ECoG coastline after TetTx injection (day -10), excluding seizures, showing no difference between eGluCl and GFP treatment at day 0 (mean±sem, same animal cohort as in Figure 3). (b) Effect of GFP or eGluCl treatment on ECoG coastline evaluated over two 6 h periods (no TetTx). Top: experimental design. The lower panels show the coastline after GFP or eGluCl treatment normalized by pre-Rx coastline (left) (ratio: eGluCl: 1.01±0.03, n=7; GFP: 1.06±0.03, n=6; mean±sem, p=0.293, Student’s t-test), or the post-Rx coastline after 5mg/kg ivermectin injection (+IVM), normalized by the baseline before ivermectin (-IVM) (ratio: eGluCl: 0.93±0.04, n=6; GFP: 1.10± 0.03, n=5; mean±sem, p=0.010, Student’s t-test). *p<0.05. (c) Post-Rx latency to fall from the accelerating rotarod on three consecutive days (average latency to fall in 3 rotarod sessions eGluCl: 84.8±12.0sec, n= 5; GFP: 75.4±15.0 sec, n=6; mean±sem, p=0.646, Student’s t-test), and subsequently on three days 24h after IVM (gray). The right panel shows the average latencies after IVM normalized to the average of the 3 test sessions before IVM (eGluCl: 1.36±0.12, n = 5, GFP: 0.96±0.05, n=6; mean±sem, p=0.009, Student’s t-test). **p<0.01. (d) Post-Rx absolute number of steps taken on an elevated grid (eGluCl: 83.5±12.7; GFP: 95.3±17.5; mean±sem, p=0.612, Student’s t-test), and subsequently after IVM (same animals as in (c)). The right panel shows the number of steps after IVM normalized to the average of the 3 test sessions before IVM (expressed as a ratio of steps taken pre-IVM, eGluCl: 0.76±0.09, n = 5; GFP: 1.04±0.08, n=6; mean±sem, p=0.045, Student’s t-test). *p<0.05.